Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL phase 3 trial of MDV3100 in chemotherapy-naive metastatic prostate cancer after failure of androgen deprivation therapy
NL-OMON39962Phase 3Recruiting
- Sponsor
- Medivation
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing MDV3100 with Placebo (2 arms). Primary endpoints: Overall survival and Radiographic progression-free survival. Started Jun 2011; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON39962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39962.